Can you tell when you’ve eaten too much ice cream? Does the eructation shake your table lamps after too many sodas? Sometimes we learn what enough is by having too much. Too bad it isn’t the same with drugs. A hundred-pound lady doesn’t need as many aspirins to get rid of a headache as a two-hundred-pound guy. And for those who take a statin because the doctor said so, why does everybody start with the same doses? With Zocor, everybody starts with 40 mg. Doesn’t anybody think that maybe 5 mg could do the trick? Hey, if one quart of white semi-gloss will cover the bathroom walls adequately, why buy a gallon unless you have a use for it elsewhere? You gonna paint those walls until the gallon is empty?
Over the last few years, the cholesterol model of cardiovascular disease is steadily being replaced by the inflammation model of CVD, putting statin drugs on the back burner because cholesterol, it is realized, has never caused a heart attack. In fact, half the scary cardiac events happen to people who have what are deemed ideal cholesterol numbers (Sachdeva, 2009). Yes, it is true that statins interfere with cholesterol manufacture by the body, not only in the liver, but also in the brain, where cholesterol is vital to the machinery of thought and function. Low cholesterol can lead to serious health issues when that machinery is interrupted. Low cholesterol levels are associated with high total mortality, even in patients with coronary heart disease (Behar, 1997) (Krumholz, 1994).
Differences between young and old, and between male and female, are recognized in the cholesterol arena, too. The impact of total cholesterol as a risk factor for heart disease decreases with age (Waverling-Rijnsburger, 1997) and for women, whose moderately elevated cholesterol may actually be beneficial (Petursson, 2012). The age cutoff for both genders is fifty (Anderson, 1987). If this information regarding age was known ten years ago, why are TV ads so adamant about getting cholesterol values below a hundred?
The personal experiences of at least one NASA astronaut have attested to the nasty effects of statins, including transient global amnesia, impaired cognition, personality changes, myopathy, neuropathy and neuromuscular degeneration. The root of all these maladies is the inhibition of Co-enzyme Q 10, a physiologically necessary substance that is blocked by Lipitor, Zocor, Crestor and the rest of the gang. Without CoQ10, mitochondria don’t work their magic at cell metabolism, where they get to burn food for energy, oxidize fatty acids, and use the electrons supplied by CoQ10 for a host of other essential activities. The pathway that makes cholesterol also makes CoQ10 in the body. Stopping one stops the other. This is so well known that statin prescriptions in Canada—for Mevachor®, Pravachol® and Lipitor®— contain a warning about CoQ 10 depletion. Merck even filed two patents for a statin-CoQ 10 combination, no. 4,933,165 and no. 4,929,437, which expired in May and June of 2007 (Koon, 2013). And you thought the drug companies had your best interest at heart, eh? The cholesterol issue is a complicated one and now, to add to the quagmire of hits and misses, is the notice that statins are implicated in the risk of developing diabetes. The endearing stars in this drama are atorvastatin (Lipitor), rosuvastatin (Crestor) and simvastatin (Zocor), brought to you by Pfizer, AstraZeneca and Merck. Atorvastatin was found to be the most influential of the three at elevating blood glucose, followed by rosuvastatin and simvastatin, in a recent Canadian study carried out at the Toronto General Hospital (Carter, 2013). From this work it may be drawn that pravastatin (Pravachol) is the safest drug related to diabetes onset. Regardless of drug of choice, or rather the physician’s choice, dose intensity also seems to make a difference in diabetes risk. Intense doses, especially at 80 mg of Zocor, increase the odds of all statin-induced adverse events (Silva, 2007), extending diabetes risk to almost ten percent of the medicated population (Preiss, 2011).
For all the hoopla that accompanied statins’ debut forty years ago into the pharmaceutical world, recounting their anti-cholesterol beneficence, it’s been discovered that their real claim to fame is being anti-inflammatory. That characteristic, it’s claimed, is more important to their raison d’etre than disrupting the cholesterol (and CoQ 10) pathway (Antonopoulos, 2012) (Mora, 2006) (Weitz-Schmidt, 2002). If so, then anti-inflammatory substances that have zero side effects might be considered. In this list will be simple things with complex mechanisms, like ginger, curcumin (from turmeric), capsaicin (from hot peppers), garlic, fish oil, bromelain (from pineapples), flaxseed oil, and zinc, among others. Aside from an allergic reaction which you already would know about, the only side effects of these ingredients are possibly foul breath (that would be the anti-vampire action) and stomach upset from too much of a good thing.
The mention of CoQ10 needs at least a little thought. Natural stores of this enzyme diminish with age. The fact that it donates electrons to multiple body processes bespeaks its importance to full function. It’s comparable to using the correct gauge extension cord with an electric weed trimmer. If the cord can’t carry the voltage, the trimmer will not work to its potential. Adding CoQ 10 to the daily regimen is a prudent decision whether taking a statin or not. Why? It helps to control blood glucose (Kolahdouz, 2013) (Mezawa, 2012).
Anderson KM, Castelli WP, Levy D.
Cholesterol and mortality. 30 years of follow-up from the Framingham study.
JAMA. 1987 Apr 24;257(16):2176-80.
Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C.
Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials.
Curr Pharm Des. 2012;18(11):1519-30.
Behar S, Graff E, Reicher-Reiss H, Boyko V, Benderly M, Shotan A, Brunner D.
Low total cholesterol is associated with high total mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) Study Group.
Eur Heart J. 1997 Jan;18(1):52-9.
Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM.
Risk of incident diabetes among patients treated with statins: population based study.
BMJ. 2013 May 23;346:f2610. doi: 10.1136/bmj.f2610.
Richard Deichmann, MD, Carl Lavie, MD, and Samuel Andrews, MD
Coenzyme Q10 and Statin-Induced Mitochondrial Dysfunction
Ochsner J. 2010 Spring; 10(1): 16–21.
Forette B, Tortrat D, Wolmark Y.
Cholesterol as risk factor for mortality in elderly women.
Lancet. 1989 Apr 22;1(8643):868-70.
Halfdan Petursson MD, Johann A. Sigurdsson MD Dr med, Calle Bengtsson MD Dr med,
Tom I. L. Nilsen Dr Philos and Linn Getz MD PhD
Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years prospective data from the Norwegian HUNT 2 study
Journal of Evaluation in Clinical Practice 18 (2012) 159–168
Risto Huupponen, Jorma Viikari
Statins and the risk of developing diabetes
BMJ. 23 MAY 2013;346:f3156
Kolahdouz Mohammadi R, Hosseinzadeh-Attar MJ, Eshraghian MR, Nakhjavani M, Khorami E, Esteghamati A.
The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients.
Minerva Gastroenterol Dietol. 2013 Jun;59(2):231-6.
CoQ 10 Supplementation with Statins
Natural Products Insider. Feb 26, 2013
Kozarevic D, McGee D, Vojvodic N, Gordon T, Racic Z, Zukel W, Dawber T.
Serum cholesterol and mortality: the Yugoslavia Cardiovascular Disease Study.
Am J Epidemiol. 1981 Jul;114(1):21-8.
Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI, Tsukahara R, Ostfeld AM, Berkman LF.
Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years.
JAMA. 1994 Nov 2;272(17):1335-40.
Mezawa M, Takemoto M, Onishi S, Ishibashi R, Ishikawa T, Yamaga M, Fujimoto M, Okabe E, He P, Kobayashi K, Yokote K.
The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study.
Biofactors. 2012 Nov-Dec;38(6):416-21.
Mora S, Ridker PM.
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)–can C-reactive protein be used to target statin therapy in primary prevention?
Am J Cardiol. 2006 Jan 16;97(2A):33A-41A.
Steven E. Nissen, M.D., E. Murat Tuzcu, M.D., Paul Schoenhagen, M.D., Tim Crowe, B.S., et al
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
N Engl J Med. January 6, 2005; 352:29-38
Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, et al
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
JAMA. 2011 Jun 22;305(24):2556-64.
Paul M Ridker, M.D., Christopher P. Cannon, M.D., David Morrow, M.D., Nader Rifai, Ph.D, et al
C-Reactive Protein Levels and Outcomes after Statin Therapy
N Engl J Med. Jan 6, 2005; 352:20-28
Rudman D, Mattson DE, Nagraj HS, Caindec N, Rudman IW, Jackson DL.
Antecedents of death in the men of a Veterans Administration nursing home.
J Am Geriatr Soc. 1987 Jun;35(6):496-502.
Sachdeva A, Cannon CP, Deedwania PC, Labresh KA, Smith SC Jr, Dai D, Hernandez A, Fonarow GC.
Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.
Am Heart J. 2009 Jan;157(1):111-117.e2.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR et al
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
Lancet. 2010 Feb 27;375(9716):735-42.
Sattar N, Taskinen MR.
Statins are diabetogenic–myth or reality?
Atheroscler Suppl. 2012 Aug;13(1):1-10.
Shah RV, Goldfine AB.
Statins and risk of new-onset diabetes mellitus.
Circulation. 2012 Oct 30;126(18):e282-4. doi: 10.1161/CIRCULATIONAHA.112.122135.
Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P.
Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Clin Ther. 2007 Feb;29(2):253-60.
Simsek S, Schalkwijk CG, Wolffenbuttel BH.
Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes—the CORALL study.
Diabet Med. 2012 May;29(5):628-31.
Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, Sachdeva R, Kesan SH, Mehta JL.
Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients.
J Investig Med. 2009 Mar;57(3):495-9.
Statins as anti-inflammatory agents
Trends in Pharmacological Sciences, 1 Oct 2002; Vol 23, Iss 10: 482-487,
Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG.
Total cholesterol and risk of mortality in the oldest old.
Lancet. 1997 Oct 18;350(9085):1119-23.
*These statements have not been evaluated by the FDA.
These products are not intended to treat, diagnose, cure, or prevent any disease.